

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

BLUEBOX PRECISION MEDICINE FUND - SHARE CLASS S (USD) ACC

BlueBox Precision Medicine Fund is a sub-fund of BlueBox Funds

MANUFACTURER: Funds Avenue SA

ISIN: LU2519375591

WEBSITE: www.blueboxfunds.com

TELEPHONE NUMBER: +352 28 32 7100

COMPETENT AUTHORITY: Funds Avenue SA is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur Financier. This PRIIP is authorised in Luxembourg.

MANAGEMENT COMPANY: Funds Avenue SA

Authorised in: This PRIIP is authorised in Luxembourg.

ISSUED ON 29/01/2024

WHAT IS THIS PRODUCT?

Type: UCITS.

Term: This product is not subject to any fixed term.

Objectives: The main objective of the Fund is to seek to maximise total return. The Fund invests globally with at least 85% of its total assets in the equity securities of companies whose predominant economic activity is in the pharmaceuticals, biotechnology and life science sectors. The overall investment strategy of the BlueBox Precision Medicine Fund is to seek out companies that will create value for the Shareholders from precision medicine: the multi-year trend of increasingly precise and targeted drug development in the pharmaceutical and biotechnology industries. The BlueBox Precision Medicine Fund will typically hold 25 to 45 positions. The holding periods are expected to be generally long (multiple years) and turnover low, although at times the BlueBox Precision Medicine Fund may utilise shorter holding periods if value is realised more quickly or unexpected events occur. The geographic focus of the strategy is global. The sector focus is predominantly pharmaceuticals, biotechnology and life science, however the BlueBox Precision Medicine Fund may also acquire shares in companies classified in other sectors with a strong pharmaceutical, biotechnology or life science element to their business. Holdings will be primarily of publicly listed companies, typically with a market capitalisation of about \$1bn or more, but the BlueBox Precision Medicine Fund will take part in initial public offerings (where the market cap may be significantly below \$1bn at listing) and it may occasionally invest in private companies where an initial public offering is strongly expected to follow within 18 months or so. The BlueBox Precision Medicine Fund may not acquire shares carrying voting rights which should enable it to exercise significant influence over the management of an issuing body. The BlueBox Precision Medicine Fund will not invest in FDIs, nor enter into any securities financing transaction within the meaning of the SFT Regulations. Should the BlueBox Precision Medicine Fund wish at a later stage to enter into any of these transactions, the Prospectus will be updated accordingly. It is currently not contemplated for the BlueBox Precision Medicine Fund to invest in Russian equities or equity related securities. Purchase and sale of shares in the Fund can be made on each Business Day. The Fund is active and managed without any reference to a benchmark. The Management Company has discretion over the composition of its portfolio subject to this objective and investment policy. Recommendation: this Fund may not be appropriate for investors who plan to withdraw their money within five years. The Fund does not intend to declare or make distributions.

Intended Retail Investor: Investment in the BlueBox Precision Medicine Fund is suitable for all investors (retail, professional clients and eligible counterparties) seeking medium to long term capital gains through investments in global equities and specifically in the pharmaceuticals, biotechnology and life science sectors. Investors should understand the risks involved in an investment of this kind, as those mentioned in the Risk Factors Annex of the Prospectus and should be able to tolerate the levels of volatility associated with equities in the pharmaceuticals, biotechnology and life science sectors and eventually accept potential losses due to market fluctuations. The BlueBox Precision Medicine Fund may not be compatible for investors outside the target market or those that are not able to bear all losses with respect to their investment. Classes of the BlueBox Precision Medicine Fund are eligible for all distribution channels (e.g., investment advice, portfolio management, non-advised sales and pure execution services).

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

RISK INDICATOR

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

1	2	3	4	5	6	7
---	---	---	---	---	---	---

Lower Risk

Higher Risk

Typically lower rewards

Typically higher rewards

The risk indicator assumes you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to cash in early. You may not be able to sell your product easily or you may have to sell at a price that significantly

impacts on how much you get back.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you.

Be aware of currency risk. In some circumstances, you may receive payments in a different currency, so the final return you will get may depend on the exchange rate between the two currencies. This risk is not considered in the indicator.

A complete description of risk factors is set out in the Prospectus in the section entitled 'Risk Factors Annex'.

PERFORMANCE SCENARIOS

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

Recommended Holding Period: 5 years			
Investment 10,000 USD		1 year	5 years (Recommended Holding period)
Scenarios			
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	3,000 USD	2,000 USD
	Average return each year	-69.97%	-27.49%
Unfavourable	What you might get back after costs	6,680 USD	8,120 USD
	Average return each year	-33.18%	-4.07%
Moderate	What you might get back after costs	10,840 USD	12,540 USD
	Average return each year	8.37%	4.64%
Favourable	What you might get back after costs	16,140 USD	19,090 USD
	Average return each year	61.44%	13.81%
<p>The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.</p> <p>The stress scenario shows what you might get back in extreme market circumstances.</p> <p>Unfavourable: This type of scenario occurred for an investment between 09/2021 and 04/2023.</p> <p>Moderate: This type of scenario occurred for an investment between 02/2017 and 02/2022.</p> <p>Favourable: This type of scenario occurred for an investment between 06/2013 and 06/2018.</p>			

WHAT HAPPENS IF FUNDS AVENUE SA IS UNABLE TO PAY OUT?

The value of a security may decline for a number of reasons which directly relate to the issuer, such as management performance, financial leverage or default. The Fund does not include any protection from future market performance, so you could lose some or all of your investment. However, your investments are deposited with a third party custodian bank, which means that in case of default of the Fund Manager, you could be able to get back the current value of your investment.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product performs. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000 is invested.

Investment 10,000 USD Scenarios	If you exit after 1 year	If you exit after 5 years
Total Costs	729 USD	2,066 USD
Annual Cost Impact (*)	7.29%	3.24% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 7.88% before costs and 4.64% after costs. We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

COMPOSITION OF COSTS

		If you exit after 1 year
One-Off Costs upon entry or exit		
Entry Costs	5.00% This is a maximum figure, only applied at the request of a distribution platform. No entry cost has ever been applied to this share class. In some cases you will be charged less, or nothing. Please refer to your financial advisor or the distributor for the actual charges.	500 USD
Exit Costs	There are no exit costs.	0 USD
Ongoing costs taken each year		
Management fees and other administrative or operating costs	2.28% of the value of your investment per year. This is an estimate based on actual costs over the last year.	228 USD
Transaction costs	0.01% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	1 USD
Incidental costs taken under specific conditions		
Performance fees	There are no performance fees.	0 USD

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MONEY OUT EARLY?

Recommended holding period: 5 years.

This should be considered a medium to long term investment, however there is no minimum term, nor are there any redemption restrictions.

HOW CAN I COMPLAIN?

In case of any unexpected problems in the understanding, trading or handling of the product, please feel free to directly contact Funds Avenue SA.

Website: www.fundsavenue.com

E-mail: info@fundsavenue.com

Telephone: +352 28 32 7100

Funds Avenue will handle your request and provide you with feedback as soon as possible.

OTHER RELEVANT INFORMATION

- Alongside this document, we invite you to carefully consult the Prospectus on our website.
- This share class launched in 2023 and there is no full calendar years performance. Previous monthly performance scenario calculations can be found at <https://swift.zeidlerlegalservices.com/priip-info/bluebox-funds>. Please note that past performance is not indicative of future performance. It cannot provide a guarantee of returns that you will receive in the future.
- Additional information for investors in Switzerland:** The representative in Switzerland is REYL & Cie Ltd, Rue du Rhône 4, CH-1204 Geneva. The prospectus, the Key Information Document, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative. Current share prices are available on www.fundinfo.com. The paying agent in Switzerland is REYL & Cie Ltd, Rue du Rhône 4, CH-1204 Geneva.